Specialized in the clinical differential diagnosis and treatment of chronic, multisystemic infectious diseases with a focus on intracellular persistence.
"Diagnostics is detective work at the cellular level. Anyone who individually treats chronic multisystem diseases like Lyme as mere joint pain is committing a fatal medical error."
Dr. Philippe Bottero is an exceptionally experienced specialist with a strict focus on clinical infectiology and immunology. He has dedicated his life to researching, diagnosing, and treating chronic, multisystemic infectious diseases that are routinely overlooked by conventional laboratories. His daily clinical work includes the millimeter-precise differential diagnostics of highly complex clinical pictures in which masked intracellular pathogens play a destructive systemic role. Through his incomparable experience in the direct, often years-long treatment of desperate patients, he brings pragmatic practical knowledge to the elite scientific discussion surrounding chronic Lyme disease and elusive co-infections. Over the past decades, he established uncompromising, practice-oriented guidelines that define the crucial difference between passive post-infectious syndromes and chronically active, biofilm-forming infections.
Integrated infectious medicine requires a radically holistic approach. Standard, two-week antibiotic protocols fail miserably with persistent infections because they only eliminate planktonic microbes. Dr. Bottero focuses clinically on the immunological detection of pathogens hidden in cysts and biofilms (Borrelia, Bartonella, Babesia). He integrates highly specific LTT tests (lymphocyte transformation tests), CD57+ cell measurements, and complex cellular immune profiles. His work impressively proves that pathogens are actively capable of tricking the immune system by barricading themselves in antibiotic-resistant colonies (biofilms) and continuously releasing immunosuppressive toxins into the tissues.
A negative ELISA antibody test clearly proves that the patient does not have Lyme disease.
Fatally wrong. Chronic Borrelia actively attack the antibody-producing B cells. A patient in the end stages of Lyme disease is often seronegative because their immune system is simply no longer capable of producing the markers sought in the ELISA.
Chronic Lyme disease (PTLDS) is a pure stress disease following successful antibiotic therapy.
Fiction. Post-Treatment Lyme Disease Syndrome is often a political term for persistent, intracellular infections that have evaded into biofilms, resisting standard antibiotics. The pathogen is still there.
"We must stop telling multisystemically ill patients they are "cured" just because our laboratory devices are not sensitive enough to isolate the pathogen entrenched in the tissue."
Presidential Member of the VBCI e.V. Scientific Advisory Board. He acts as a crucial diagnostic corrective, linking global clinical guidelines with real-world patient care.
Why do some Lyme disease patients not recover despite antibiotics? Learn how biofilm structures and persistence forms (cysts, L-forms) evade antibiotics and what modern combination therapies can do about it.